- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.07. | Coiled Therapeutics develops new formulation for AO-252 | 1 | Investing.com | ||
| 07.07. | Coiled Therapeutics - Coiled Advances Next-Generation AO-252 Formulation | - | RNS | ||
| 24.06. | Coiled Therapeutics - Company Presentation | - | RNS | ||
| 24.06. | Coiled Therapeutics - Result of AGM | - | RNS | ||
| 24.06. | Coiled Therapeutics - Appointment of Independent Non-Executive Director | - | RNS | ||
| COILED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.06. | Coiled Therapeutics - Life Sciences Investor Forum | - | RNS | ||
| 18.06. | Coiled Therapeutics - Proactive One2One Investor Forum | - | RNS | ||
| 17.06. | Coiled Therapeutics - Grant of Share Options | 1 | RNS | ||
| 17.06. | Coiled Therapeutics beruft renommierte Onkologen in medizinischen Beirat | - | Investing.com Deutsch | ||
| 17.06. | Coiled Therapeutics establishes medical advisory board | 1 | Investing.com | ||
| 17.06. | Coiled Therapeutics - Establishment of Medical Advisory Board | - | RNS | ||
| 08.06. | Coiled Therapeutics beruft Professor Ozgur Sahin in den wissenschaftlichen Beirat | 3 | Investing.com Deutsch | ||
| 08.06. | Coiled Therapeutics appoints Ozgur Sahin as scientific advisor | 1 | Investing.com | ||
| 08.06. | Coiled Therapeutics - Appointment of Ozgur Sahin as Scientific Advisor | - | RNS | ||
| 29.05. | Coiled Therapeutics - Issue of Equity | - | RNS | ||
| 27.05. | Coiled Therapeutics - Notice of Annual General Meeting | - | RNS | ||
| 19.05. | Coiled Therapeutics shares rise as cross trading begins in New York | 1 | Alliance News | ||
| 19.05. | Coiled Therapeutics startet Handel am US-Markt OTCQB | 1 | Investing.com Deutsch | ||
| 19.05. | Coiled Therapeutics begins trading on US OTCQB market | 2 | Investing.com | ||
| 19.05. | Coiled Therapeutics - Commencement of Trading on US OTCQB Venture Market | - | RNS |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,330 | -0,21 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,640 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 41,270 | 0,00 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 110,55 | +0,14 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,34 | -0,07 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| BEAM THERAPEUTICS | 30,990 | -0,03 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| TANGO THERAPEUTICS | 28,350 | -0,04 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,480 | +0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,505 | +0,01 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,79 | -0,02 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| CG ONCOLOGY | 72,55 | +0,07 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| TREVI THERAPEUTICS | 16,515 | -0,03 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,295 | -0,15 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,300 | 0,00 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| TARSUS PHARMACEUTICALS | 59,28 | -0,06 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth |
COILED THERAPEUTICS PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,097 Euro und damit +3,18 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COILED THERAPEUTICS PLC finden Sie auf Wallstreet Online.